Acumen Pharmaceuticals Future Growth
Future criteria checks 0/6
Acumen Pharmaceuticals's earnings are forecast to decline at 7.8% per annum while its annual revenue is expected to grow at 70.7% per year. EPS is expected to decline by 5.1% per annum. Return on equity is forecast to be -116.1% in 3 years.
Key information
-7.8%
Earnings growth rate
-5.1%
EPS growth rate
| Biotechs earnings growth | 27.2% |
| Revenue growth rate | 70.7% |
| Future return on equity | -116.1% |
| Analyst coverage | Low |
| Last updated | 06 Dec 2024 |
Recent future growth updates
Recent updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | N/A | -135 | -161 | -166 | 2 |
| 12/31/2026 | N/A | -121 | -137 | -141 | 2 |
| 12/31/2025 | N/A | -119 | -117 | -120 | 4 |
| 12/31/2024 | N/A | -95 | -80 | -80 | 4 |
| 9/30/2024 | N/A | -82 | -67 | -67 | N/A |
| 6/30/2024 | N/A | -65 | -56 | -56 | N/A |
| 3/31/2024 | N/A | -56 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -52 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -49 | -46 | -46 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -45 | -37 | -37 | N/A |
| 12/31/2022 | N/A | -43 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -32 | -26 | -26 | N/A |
| 3/31/2022 | N/A | -83 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -101 | -18 | -18 | N/A |
| 9/30/2021 | 0 | -93 | -17 | -17 | N/A |
| 6/30/2021 | 1 | -92 | -11 | -11 | N/A |
| 3/31/2021 | 1 | -32 | -8 | -8 | N/A |
| 12/31/2020 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2019 | 2 | -8 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABOS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABOS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABOS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABOS is forecast to have no revenue next year.
High Growth Revenue: ABOS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABOS is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 23:04 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acumen Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |